Mi Nk Therapeutics, Inc. INKT
We take great care to ensure that the data presented and summarized in this overview for MiNK Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INKT
View all-
Vanguard Group Inc Valley Forge, PA234KShares$168,6110.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$119,9990.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny107KShares$76,8140.0% of portfolio
-
Geode Capital Management, LLC Boston, MA98KShares$70,5460.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$62,7810.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL51.7KShares$37,2440.0% of portfolio
-
State Street Corp Boston, MA25.5KShares$18,3700.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC15.3KShares$11,0310.0% of portfolio
-
Two Sigma Securities, LLC New York, NY11.9KShares$8,5940.0% of portfolio
-
Northern Trust Corp Chicago, IL11.1KShares$7,9720.0% of portfolio
Latest Institutional Activity in INKT
Top Purchases
Top Sells
About INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Insider Transactions at INKT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2024
|
Ulf Wiinberg |
BUY
Grant, award, or other acquisition
|
Direct |
18,295
+12.88%
|
$0
$0.82 P/Share
|
|
Sep 03
2024
|
Peter Behner |
BUY
Grant, award, or other acquisition
|
Direct |
18,753
+14.65%
|
$0
$0.82 P/Share
|
|
Sep 03
2024
|
Barbara Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
21,649
+14.65%
|
$0
$0.82 P/Share
|
|
Sep 03
2024
|
Brian Corvese |
BUY
Grant, award, or other acquisition
|
Direct |
21,802
+5.1%
|
$0
$0.82 P/Share
|
|
Jun 03
2024
|
Ulf Wiinberg |
BUY
Grant, award, or other acquisition
|
Direct |
15,077
+12.51%
|
$0
$0.99 P/Share
|
|
Jun 03
2024
|
Barbara Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
17,841
+14.59%
|
$0
$0.99 P/Share
|
|
Jun 03
2024
|
Peter Behner |
BUY
Grant, award, or other acquisition
|
Direct |
15,454
+14.59%
|
$0
$0.99 P/Share
|
|
Jun 03
2024
|
Brian Corvese |
BUY
Grant, award, or other acquisition
|
Direct |
17,967
+4.48%
|
$0
$0.99 P/Share
|
|
Mar 01
2024
|
Brian Corvese |
BUY
Grant, award, or other acquisition
|
Direct |
18,816
+4.9%
|
$0
$0.95 P/Share
|
|
Mar 01
2024
|
Ulf Wiinberg |
BUY
Grant, award, or other acquisition
|
Direct |
15,790
+14.88%
|
$0
$0.95 P/Share
|
|
Mar 01
2024
|
Barbara Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
18,685
+17.74%
|
$0
$0.95 P/Share
|
|
Mar 01
2024
|
Peter Behner |
BUY
Grant, award, or other acquisition
|
Direct |
16,185
+17.74%
|
$0
$0.95 P/Share
|
|
Dec 01
2023
|
Barbara Ryan |
BUY
Grant, award, or other acquisition
|
Direct |
17,068
+20.08%
|
$17,068
$1.04 P/Share
|
|
Dec 01
2023
|
Peter Behner |
BUY
Grant, award, or other acquisition
|
Direct |
14,784
+20.08%
|
$14,784
$1.04 P/Share
|
|
Dec 01
2023
|
Ulf Wiinberg |
BUY
Grant, award, or other acquisition
|
Direct |
14,424
+16.21%
|
$14,424
$1.04 P/Share
|
|
Dec 01
2023
|
Brian Corvese |
BUY
Grant, award, or other acquisition
|
Direct |
17,188
+4.72%
|
$17,188
$1.04 P/Share
|
|
Oct 16
2023
|
Agenus Inc |
BUY
Open market or private purchase
|
Direct |
429
+0.0%
|
$429
$1.1 P/Share
|
|
Oct 13
2023
|
Agenus Inc |
BUY
Open market or private purchase
|
Direct |
19,373
+0.09%
|
$19,373
$1.1 P/Share
|
|
Oct 12
2023
|
Agenus Inc |
BUY
Open market or private purchase
|
Direct |
3,173
+0.01%
|
$3,173
$1.1 P/Share
|
|
Oct 11
2023
|
Jennifer Buell Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
695,750
-74.98%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 280K shares |
|---|